Settled expectations, the six-year rule, and developments in USPTO policy

Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Regulatory and patent teams must align, say Amgen, Genentech, ORIC

EPO starts using AI for minutes but no access to transcripts for parties

LSPN Fall: AI agents are taking on patent work. What’s left for lawyers?

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients

In-house counsel rethink patent filing strategies as costs mount

Fenwick hires NY partner to advise on regulatory matters

Oura targets Ultrahuman’s redesigned smart ring following import ban

Weil collapse leaves IP talent facing uncertain future after major expansion

Settled expectations, the six-year rule, and developments in USPTO policy

More on this story

Editor's picks

Editor's picks

More features